What are the reimbursement conditions for lorlatinib and which areas are covered by medical insurance?

Lorlatinib, a targeted drug for the treatment of ALK-positive non-small cell lung cancer, has been officially launched in China and included in the national medical insurance directory. This means that patients who meet the relevant medical insurance reimbursement conditions can reduce their medication burden through medical insurance and obtain more convenient drug supply. Generally speaking, medical insurance reimbursement is applicable to patients with basic medical insurance for urban and rural residents or employee medical insurance. However, the specific reimbursement policies will vary depending on the medical insurance policies of various provinces and cities. Patients need to consult local medical institutions or medical insurance departments for detailed information.

The basic conditions for medical insurance reimbursement usually include that the patient is diagnosed with ALK positive non-small cell lung cancer and meets the indications for lorlatinib prescribed by the doctor. In addition, patients need to purchase and use the drug at a medical institution with designated medical insurance qualifications, and the relevant medical expenses must be declared in accordance with the prescribed procedures. Some regions may impose requirements on drug dosage, course of treatment, and efficacy evaluation to ensure rational use of drugs and standardized use of medical insurance funds.

In terms of coverage areas, the medical insurance policy for lorlatinib has been gradually promoted in many provinces and cities, including Beijing, Shanghai, Guangzhou, Jiangsu and other more economically developed regions, which have been included in the medical insurance catalog to ensure that more patients can enjoy reimbursement benefits. With the improvement and expansion of medical insurance policies, it is expected that more regions will gradually realize medical insurance coverage of lorlatinib in the future, benefiting a wider range of patient groups.

In terms of price, the market price of lorlatinib is relatively high, ranging from RMB 10,000 to RMB 20,000. The actual payment after reimbursement depends on the reimbursement ratio of the patient's regional medical insurance and the individual medical insurance policy. There are original drugs and lower-priced generic drugs in foreign markets. The price of original drugs in Turkey is about more than 7,000 yuan, and the price of original drugs in Hong Kong is as high as 30,000 yuan. However, the price of generic drugs in places such as Laos and Bangladesh is more affordable, about more than 1,000 yuan, and the ingredients are basically the same as the original drugs. Patients should comprehensively consider their economic status and drug sources when choosing, and give priority to purchasing through formal channels.

Reference materials:https://www.drugs.com/